Eli Lilly (LLY) is mentioned as another company involved in the weight-loss drug market, alongside Novo Nordisk, with their drug Zepbound also being part of the "anti-obesity deal."
Source Post
Oval Office Emergency as Trump signs miracle weight loss deal with America!? #nvo #invest #finance #fyp
Nov 7, 2025
The creator discusses the "anti-obesity deal" signed by Donald Trump, which aims to lower the cost of weight-loss drugs like Ozempic and Wegovy. The creator highlights that Novo Nordisk (NVO) and Eli Lilly (LLY) are the companies behind these drugs and expresses a bullish sentiment on Novo Nordisk, stating they are buying the stock at $48, which they identify as resistance.
Linked Mentions
Tickers discussed in this post
The creator is buying Novo Nordisk (NVO) stock at $48, seeing it as a buying opportunity despite resistance, due to the company's role in the weight-loss drug market and the "anti-obesity deal."
Linked Signals
Tracked calls opened from this post
NVObuy opened Nov 7, 2025
+10.16%